A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors.

Next Previous
Trial Profile

A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Erlotinib (Primary) ; Everolimus (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top